Healthcare
Genus plc(GENSF)
Live Price
Offline$31.07
-11.24% today
1Y Change
+19.43%
Window
Jun 25, 2025 → Jun 22, 2026
- Market Cap
- $1.56B
- Revenue Growth
- +0.6%
- EPS Growth
- +108.3%
- Dividend Yield
- 1.4%
Coverage: 255 bars · Jun 25, 2025 → Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Genus plc (GENSF) is a Healthcare stock with a market cap of $1.56B and listed on OTC. The stock last traded around $31.07 and up 19.4% across the available one-year price window (Jun 25, 2025 → Jun 22, 2026). Baseline metrics include revenue growth of +0.6%, EPS growth of +108.3%, a dividend yield of 1.4%. What stands out right now is revenue +0.6%, EPS +108.3%, free cash flow +852.9% with operating margin 9.8% and ROIC 6.0%. The dividend is present but secondary, with a yield around 1.4%. Valuation already assumes a fairly strong business story at P/E 32.6 and price/sales 2.3. Stock Foundry combines GENSF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+0.6% vs +7.6% peer median
Operating Margin
Below sector median
+9.8% vs +19.4% peer median
P/E
Below sector median
32.6 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating story is still moving forward
Revenue is running at +0.6% and EPS at +108.3%, with operating margin around 9.8%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 1.4%, which matters if the thesis depends on income as much as growth.
Benchmark Edge
GENSF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
GENSF
—
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
GENSF Max Drawdown
-16.85%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for GENSF and SPY.
Company Overview
Genus plc
Other OTC
Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand. The company also sells bull semen and embryos to breed calves with various characteristics for milk and beef production under the ABS, Genus, and Bovec brands. In addition, it offers technical services to farmers. The company was incorporated in 1994 and is based in Basingstoke, the United Kingdom.
- Leadership
- Jorgen Kokke
- IPO Date
- Sep 11, 2009
- Employees
- 3.5k
- Street Address
- Matrix House
- Mailing
- Basingstoke, RG21 4DZ
- Region
- Basingstoke, GB
- Reporting Currency
- USD
- Investor Line
- 44 1256 347 100
- Last Updated
- Apr 29, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 32.6
- EV/EBITDA
- 16.1
- Price/Sales
- 2.3
- Price/Book
- 3.1
Growth
- Revenue
- +0.6%
- EPS
- +108.3%
- Free Cash Flow
- +852.9%
Profitability
- Gross Margin
- 100.1%
- Operating Margin
- 9.8%
- Net Margin
- 7.1%
- ROE
- 9.7%
- ROIC
- 6.0%
Balance Sheet
- Debt/Equity
- 0.55
- Current Ratio
- 2.25
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.